 |
Ocala Oncology's Dr. Thomas Cartwright to present findings on survival outcomes for patients with metastatic colorectal cancerSeptember 21, 2011 |
|
|
|
|
Poster featured as part of the Poster Session at the 2011 European Multidisciplinary Cancer Congress Ocala, Fla. and The Woodlands, Texas (Sept. 21, 2011) – Ocala Oncology, an affiliate of The US Oncology Network and a comprehensive oncology/hematology care center with two locations in Ocala, Fla., announced today that Thomas Cartwright, M.D. will present a poster titled "Survival outcomes with use of bevacizumab beyond progression (BBP) in metastatic colorectal cancer (MCRC) patients (Pts)" at the 2011 European Multidisciplinary Cancer Congress (EMCC) in Stockholm, Sweden. Dr. Cartwright's poster will be part of the EMCC Poster Session on "Gastrointestinal Malignancies - Colorectal Cancer," scheduled for 9:30 am to noon, Sunday, Sept. 25 in Stockholm in the Exhibition Hall, Hall C. To view Dr. Cartwright's poster and attend his poster presentation, please see poster board 290. "We're very excited that the data has been accepted for presentation at the Congress," said Dr. Cartwright. "As a member of the Pharmacy and Therapeutics Committee and a member of the Pathways Task Force, physician advisory groups within The US Oncology Network, I believe that outcomes studies, such as this, are integral in our ability to advance the quality of cancer care." Dr. Cartwright and other members of the P&T Committee and Pathways Task Force engage the expertise of McKesson Specialty Health's Healthcare Informatics (HI) group who can access the data from providers entered into the electronic health record system, iKnowMed™, to test and validate the efficacy and safety of cancer treatments by comparing real-life data from patients treated in community-based cancer care centers with published clinical trials data. The European CanCer Organisation (ECCO) will publish abstracts for the 2011 European Multidisciplinary Cancer Congress online two weeks prior to the Congress; for general viewing online as early as Sept. 12, visit www.ecco-org.eu. Dr. Cartwright's abstract in the programme and abstract book (available on USB at the Congress) is 6.150. The European Multidisciplinary Cancer Congresses are the only multidisciplinary and multi-professional educational opportunities in oncology to take place in Europe. The European Multidisciplinary Cancer Congresses brings together the 16th ECCO, 36th European Society for Medical Oncology (ESMO), and the 30th European Society for Therapeutic Radiotherapy & Oncology (ESTRO) Congresses to form an organized partnership with ECCO founding members European Society of Surgical Oncology (ESSO), European Association for Cancer Research (EACR), European Nursing Society (EONS) and the European Society for Pediatric Oncology (SIOPE). The 2011 EMCC integrates basic and translational science, surgery, radiotherapy, medical oncology, advocacy and care into one multidisciplinary mass gathering and celebration of European basic, translational and clinical studies. The first jointly organized multidisciplinary Cancer Congress, ECCO 15/ESMO 34, took place in Berlin, Sept. 21 - 24 2009, and marked a milestone in advancing cancer research and treatment across Europe by drawing a record multi-stakeholder audience of nearly 15,000 participants, and presenting more cutting-edge and late breaking data than ever before. About Ocala Oncology Ocala Oncology is united in healing with The US Oncology Network, one of the nation's largest community-based cancer treatment and research networks focused on advancing cancer care in America. As an affiliate of The US Oncology Network, Ocala Oncology is united with more than 1,000 physicians and 10,000 cancer professionals nationwide. Ocala Oncology participates in clinical trials through US Oncology Research, which has helped to develop 43 FDA approved cancer therapies. For more information, visit www.ocalaoncology.com or www.usoncology.com. About McKesson Specialty Health PR ContactClaire Crye, McKesson Specialty Health Hayley Creasey, Ocala Oncology |
||||
